Previous 10 | Next 10 |
Berwyn, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results of an interim analysis from a dou...
Annovis Bio ([[ANVS]] +4.9%) has signed an agreement for up to 10 kg of GMP-manufactured ANVS401 to support the Company's planned late-stage studies in Alzheimer's in Down syndrome, PD and AD."With preliminary data expected to be reported from these trials beginning in the first quarter,...
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit. About The Investor Summit The Investor Summit (former...
Berwyn, Pennsylvania--(Newsfile Corp. - March 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it signed an agreement for up to 10 kg of...
Berwyn, Pennsylvania--(Newsfile Corp. - March 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the Japan Patent Office (JPO) granted the...
Berwyn, Pennsylvania--(Newsfile Corp. - March 9, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and...
BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D.,...
Annovis Bio ([[ANVS]] +30.0%) announces that the European Patent Office ((EPO)) has granted it a patent for a method of treating acute nerve and brain injuries by administering ANVS405 therapy after the injury.ANVS401 and ANVS405 are Annovis' drug candidates that aim to treat chronic and acut...
Gainers: ATA Creativity Global (AACG) +204%.Anavex Life Sciences (AVXL) +81%.Lizhi (LIZI) +76%.CPS Technologies (CPSH) +48%.Annovis Bio (ANVS) +43%.Sify Technologies (SIFY) +42%.Tian Ruixiang (TIRX) +40%.Cyclerion Therapeutics (CYCN) +39%.Cyclo Therapeutics (CYTH) +33%.Ato...
Gainers: Anavex Life Sciences (AVXL) +94%, Annovis Bio (ANVS) +50%, Atossa Therapeutics (ATOS) +40%, Cyclerion Therapeutics (CYCN) +40%, Cyclo Therapeutics (CYTH) +33%.Losers: Tyme Technologies (TYME) -36%, Isoray (ISR) -19%, Lannett...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...